97: Four-Year PSA Response Rate as a Predictive Measure in Intermediate Risk Prostate Cancer Treated with Ablative Therapies: The Sprat Analysis
- Resource Type
- Source
- Radiotherapy and Oncology. 163:S43
- Subject
Oncology medicine.medical_specialty biology business.industry Measure (physics) Sprat Psa response Hematology biology.organism_classification medicine.disease Prostate cancer Internal medicine Ablative case medicine Radiology, Nuclear Medicine and imaging business Intermediate risk - Language
- ISSN
- 0167-8140